Earnings Ahead

ORIC - ORIC Pharmaceuticals

8.4 0.11 1.33

ORIC Pharmaceuticals

ORIC Pharmaceuticals

About

Profile


Headquarters

South San Francisco, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

ORIC



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • ORIC Pharmaceuticals GAAP EPS of -$0.52 beats by $0.02
  • ORIC Pharmaceuticals surges 43% on Pfizer collaboration, investment
  • ORIC Pharmaceuticals GAAP EPS of -$0.63 misses by $0.07
  • ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
  • ORIC Pharmaceuticals rallies after CEO adds $1.3M shares
  • ORIC Pharmaceuticals GAAP EPS of -$0.59 misses by $0.02
  • ORIC Pharmaceuticals CEO buys common stock worth $1.7M
  • Oric stock slides after H.C. Wainwright downgrades to neutral
  • ORIC sinks amid downgrades after ending cancer trial for lead asset
  • Oric abandons lead candidate ORIC-101 for prostate cancer, solid tumors
  • ORIC Pharmaceuticals GAAP EPS of -$0.58 in-line
  • ORIC Pharma wins regulatory nod in South Korea to start trial for cancer candidate
  • ORIC Pharmaceuticals adds Angie You to board of directors
  • ORIC Pharmaceuticals EPS beats by $0.11
  • GRPH, WDC, ORIC and CCXI among after hours movers
  • ORIC Pharma recovers some of Thursday's deep losses on Jefferies note; shares up 12%
  • ORIC Pharma shares shed one-third on prostate cancer data, hit 52-week low
  • Merus, Nutriband leads healthcare gainers; Osmotica Pharmaceuticals, Prelude Therapeutics among major losers
  • ORIC Pharma reports data from Phase 1b trial of ORIC-101 + enzalutamide in prostate cancer
  • ORIC Pharma gets FDA nod to start clinical trial for CD73-targeted cancer therapy
Date Price Open High Low Vol Change ER
Mar 22 4.76 4.38
5.00
3.94
9.00M -28.74%
Mar 21 6.68 6.86
6.96
6.53
275.63K -1.47%
Mar 18 6.78 6.60
7.19
6.43
1.67M 2.26%
Mar 17 6.63 6.25
6.65
6.14
427.95K 4.41%
Mar 16 6.35 6.47
6.47
5.83
685.38K 3.76%
 
Mar 15 6.12 6.32
6.34
5.95
576.51K -2.86%
Mar 14 6.30 7.06
7.21
6.26
439.25K -11.39%
Mar 11 7.11 7.46
7.90
6.97
211.47K -2.6%
Mar 10 7.30 7.39
7.46
7.11
201.55K -3.95%
Mar 9 7.60 7.00
7.97
6.98
633.41K 9.04%
Mar 8 6.97 6.85
7.18
6.54
219.34K 2.05%
Mar 7 6.83 7.00
7.50
6.68
225.31K -0.44%
Mar 4 6.86 7.20
7.66
6.82
146.29K -4.85%
Mar 3 7.21 7.75
7.75
7.03
228.92K -5.63%
Mar 2 7.64 7.72
7.77
7.49
191.26K -0.52%
Mar 1 7.68 7.88
8.12
7.57
154.32K -1.03%
Feb 28 7.76 8.15
8.36
7.70
145.89K -4.43%
Feb 25 8.12 7.87
8.29
7.78
179.85K 3.57%
Feb 24 7.84 7.33
7.86
7.26
587.92K 1.42%
Feb 23 7.73 8.15
8.25
7.68
154.00K -3.74%